Hypertrophy, Left Ventricular Clinical Trial
Official title:
Clinical Study Protocol M10-221 The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02237339 -
Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?
|
Phase 4 | |
Completed |
NCT00041418 -
Cardiac MR of Subclinical CVD: Impact of Age
|
N/A | |
Completed |
NCT00005373 -
Racial Differences in the Coronary Microcirculation
|
N/A | |
Recruiting |
NCT00989508 -
Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy
|
Phase 2/Phase 3 | |
Completed |
NCT03482934 -
Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate
|
||
Completed |
NCT03415750 -
Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants
|
Phase 4 | |
Completed |
NCT02973607 -
Effects of a Reduction in Renal Function on Cardiovascular Structure and Function
|
||
Completed |
NCT03749551 -
Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study
|
||
Completed |
NCT01976689 -
New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation
|
N/A | |
Active, not recruiting |
NCT05713916 -
Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy
|
N/A | |
Recruiting |
NCT00552851 -
Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
|
Phase 4 | |
Active, not recruiting |
NCT03094143 -
Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS
|
N/A | |
Completed |
NCT02444689 -
EMPower: Electronic Media Powering Positive Health Changes in Youth
|
N/A | |
Completed |
NCT00108082 -
The CLEVER Study - Coreg And Left Ventricular Mass Regression
|
Phase 3 | |
Withdrawn |
NCT03315832 -
Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study
|
Phase 2/Phase 3 | |
Completed |
NCT03180593 -
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
|
Phase 4 | |
Completed |
NCT01144039 -
Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair
|
Phase 4 | |
Completed |
NCT00045994 -
The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling
|
Phase 2 | |
Active, not recruiting |
NCT02599480 -
Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure
|
Phase 2 | |
Active, not recruiting |
NCT04862273 -
Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis
|